Judith Campisi

This inventor holds 30 USPTO granted patents and 13 published patent applications, plus 2 CIPO patents and 3 EPO patents. Top assignees: Buck Institute for Research on Aging, Unity Biotechnology, Inc., Mayo Foundation for Medical Education and Research. Active years: 1996-2025.

USPTO Granted Patents = 30 (Patent Applications = 13)

% Patents Active = 80.0

CIPO Patents = 2 (Patent Applications = 3)

EPO Patents = 3 (Patent Applications = 6)

Average Co-Inventor Count = 4.5

ph-index = 7

Forward Citations = 147(Granted Patents)

Company Filing History:

21 out of 51

Buck Institute for Research on Aging

patents

17 out of 41

Unity Biotechnology, Inc.

patents

16 out of 1,802

Mayo Foundation for Medical Education and Research

patents

4. 7 out of 15,964

University of California

patents

5. 4 out of 3,790

Johns Hopkins University

patents

6. 2 out of 3

California Pacific Medical Center Research Institute

patents

7. 2 out of 80

Erasmus University Medical Center

patents

8. 1 out of 1

Buck Institute for Research Aging

patent

9. 1 out of 15

California Pacific Medical Center

Kythera Biopharmaceuticals, Inc.

patents

12. 1 out of 18

Universitat Fur Bodenkultur Wien

patents

where one patent can have more than one assignee

Years Active: 1996-2025

Loading Chart...

Areas of Expertise:

Senescence-Associated Diseases

Ocular Disease Treatment

Cardiovascular Disease

Neurodegenerative Conditions

Senescent Cell Elimination

Biomarkers for Senescence

Pulmonary Conditions

Osteoarthritis Treatment

Transgenic Mouse Models

Immunogenic Compositions

Bcl-xL Selective Inhibitors

Sulfonamide Inhibitors

30 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12285427 - Treatment of a senescence-associated ocular disease or disorder using a Bcl-xL selective inhibitor (2025-04-29),

2. 11980616 - Treating liver disease by selectively eliminating senescent cells (2024-05-14),

3. 11963957 - Treating cardiovascular disease by selectively eliminating senescent cells (2024-04-23),

4. 11814680 - Biomarkers for detecting senescent cells (2023-11-14),

5. 11351167 - Treating cognitive decline and other neurodegenerative conditions by selectively removing senescent cells from neurological tissue (2022-06-07),

6. 10655144 - Nucleic acid construct with a p16 promoter that causes a prodrug converting enzyme to be expressed specifically in senescent cells (2020-05-19),

7. 10478433 - Unit dose of an aryl sulfonamide that is effective for treating eye disease and averting potential vision loss (2019-11-19),

8. 10478432 - Compositions of matter for treatment of ophthalmic conditions by selectively removing senescent cells from the eye (2019-11-19),

9. 10328073 - Use of sulfonamide inhibitors of BCL-2 and BCL-xL to treat ophthalmic disease by selectively removing senescent cells (2019-06-25),

10. 10328058 - Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques (2019-06-25),

11. 10279018 - Immunogenic compositions for inducing an immune response for elimination of senescent cells (2019-05-07),

12. 10258618 - Treating pulmonary conditions by selectively removing senescent cells from the lung using an intermittent dosing regimen (2019-04-16),

13. 10213426 - Method of optimizing conditions for selectively removing a plurality of senescent cells from a tissue or a mixed cell population (2019-02-26),

14. 10130628 - Treatment of joint pain (2018-11-20),

15. 10010546 - Treatment of ophthalmic conditions by selectively removing senescent cells from the eye (2018-07-03),

Title: Judith Campisi - Pioneering Inventor from Berkeley, CA

Introduction: Judith Campisi is a renowned inventor based in Berkeley, CA, known for her groundbreaking work in the field of biogerontology and cancer research.

Latest Patents: Judith Campisi holds several patents related to cellular senescence and its implications in aging and cancer treatment.

Career Highlights: With a distinguished career spanning over several decades, Campisi has made significant contributions to the understanding of cellular senescence and its role in age-related diseases. She has published numerous research papers and received several prestigious awards for her innovative work.

Collaborations: Campisi has collaborated with leading scientists, research institutions, and pharmaceutical companies worldwide to further explore the potential applications of her research in developing novel therapies for age-related conditions.

Conclusion: Judith Campisi's pioneering work continues to inspire new generations of inventors and researchers in the fields of biogerontology and cancer biology. Her dedication to advancing scientific knowledge and improving human health makes her a true trailblazer in the world of innovation.